Boston Therapeutics Announces Clinical Study Final Results Indicate That SUGARDOWN(R) Reduced the Post-Meal Elevation of Blood Glucose by up to 61% in Healthy Volunteers
MANCHESTER, NH, Jan 28, 2013 (MARKETWIRE via COMTEX) --
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or
"the Company"), a developer of complex carbohydrates to treat
diabetes and inflammatory diseases, today announced the results of a
clinical study conducted at the University of Sydney in Australia
that showed the post-meal incremental area under the curve (iAUC) for
glucose and insulin were significantly lower following consumption of
SUGARDOWN(R) chewable dietary supplement tablets prior to a high
carbohydrate meal of rice in a dose-dependent manner. This resulted
in a reduction of up to 61% in post-meal elevation of blood glucose
compared with the rice consumed alone. On average, there was a 32%
reduction in the post-meal iAUC for glucose and a 24% reduction in
post-meal insulin response for the 10 volunteers in the study. No
severe adverse effects were reported or observed during the study.
"These study results demonstrate that SUGARDOWN(R) dietary supplement
tablets can have a significant effect in reducing post-meal glucose
and insulin responses," said David Platt, Ph.D., Chief Executive
Officer, Boston Therapeutics. "Such a nutritional approach may be
valuable in the management of blood sugar and could enhance the role
of functional dietary supplements as part of a diabetes management
SUGARDOWN(R) tablets data were collected for post-meal blood sugar
elevation with a 50g glucose challenge. In a randomized, crossover
design study, SUGARDOWN(R) was tested at two doses in 10 healthy,
non-smoking subjects (6 males, 4 females; ages 25.6-36.8;
BMI=25.5-28.7). After an overnight fast of at least 10 hours,
subjects were randomized to one of three test meals. Each jasmine
rice-based meal was served to subjects in a fixed portion containing
50 grams of available carbohydrate (from 63 grams dry weight rice)
and 250ml of plain water. Each of the three test meals were consumed
on two different visits by each subject, for a total of 6 test meals
over 6 separate test sessions.
A total of eight blood samples were collected from each subject
during a test session to measure both blood glucose and insulin
levels. Finger-prick blood samples were taken at time -10, 0, 15, 30,
45, 60, 90 and 120 minutes, with time 0 corresponding to the start of
rice consumption. For each time point, plasma glucose and insulin
concentrations were determined, and the incremental area iAUC for
each test meal was calculated; parametric statistical tests
(repeated-measures ANOVA and the Fisher PLSD test) were used to
determine whether there were any significant differences among the
plasma glucose and insulin iAUC responses for each test meal.
SUGARDOWN(R) is a non-systemic chewable tablet
designed to reduce post-meal elevation of blood glucose. SUGARDOWN(R)
is a proprietary polysaccharide designed to be taken before meals and
works in the gastrointestinal track to block the action of
carbohydrate-hydrolyzing enzymes which break down carbohydrates into
glucose and release them into the bloodstream.
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered
in Manchester, NH, (OTCQB: BTHE) is a leader in the field of complex
carbohydrates. The Company's initial product pipeline is focused on
developing and commercializing therapeutic molecules for diabetes:
SUGARDOWN(R), a non-systemic chewable dietary supplement tablet
designed to reduce the elevation in post-meal blood glucose; BTI-7, a
new, chewable tablet formulation of the diabetes drug metformin
hydrochloride; PAZ320, a non-systemic compound designed to reduce
post-meal glucose elevation, and IPOXYN(TM), an injectable
anti-necrosis drug specifically designed to treat lower limb ischemia
associated with diabetes. More information is available at
www.bostonti.com and www.sugardown.com.
FORWARD-LOOKING STATEMENTS: Any statements in this news release about
future expectations, plans and prospects for the Company constitute
forward-looking statements as defined in the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on management's current
expectations and are subject to a number of factors and
uncertainties, which could cause actual results to differ materially
from those described in such statements.
More information about those risks and uncertainties is contained and
discussed in the Company's most recent quarterly or annual report and
in the Company's other reports filed with the Securities and Exchange
Commission. The forward-looking statements represent the Company's
views as of the date of this news release and should not be relied
upon to represent the Company's views as of a subsequent date. While
the Company anticipates that subsequent events may cause the
Company's views to change, the Company disclaims any obligation to
update such forward-looking statements.
Boston Therapeutics, Inc.
Director of Investor Relations
SOURCE: Boston Therapeutics, Inc.
[ Back To Cisco News 's Homepage ]